Achieving efficient analysis of multiple pathological indicators has great significance for breast cancer prognosis and therapeutic decision-making. In this study, we aim to explore a deep multi-task learning (MTL) framework for collaborative prediction of histological grade and proliferation marker (Ki-67) status in breast cancer using multi-phase dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). In the novel design of hybrid multi-task architecture (HMT-Net), co-representative features are explicitly distilled using a feature extraction backbone. A customized prediction network is then introduced to perform soft-parameter sharing between two correlated tasks. Specifically, task-common and task-specific knowledge is transmitted into tower layers for informative interactions. Furthermore, low-level feature maps containing tumor edges and texture details are recaptured by a hard-parameter sharing branch, which are then incorporated into the tower layer for each subtask. Finally, the probabilities of two histological indicators, predicted in the multi-phase DCE-MRI, are separately fused using a decision-level fusion strategy. Experimental results demonstrate that the proposed HMT-Net achieves optimal discriminative performance over other recent MTL architectures and deep models based on single image series, with the area under the receiver operating characteristic curve of 0.908 for tumor grade and 0.694 for Ki-67 status. Benefiting from the innovative HMT-Net, our proposed method elucidates its strong robustness and flexibility in the collaborative prediction task of breast biomarkers. Multi-phase DCE-MRI is expected to contribute valuable dynamic information for breast cancer pathological assessment in a non-invasive manner.

Nuclear medicine is rapidly evolving with new molecular imaging targets and advanced computational tools that promise to enhance diagnostic precision and personalized therapy. Recent years have seen a surge in novel PET and SPECT tracers, such as those targeting prostate-specific membrane antigen (PSMA) in prostate cancer, fibroblast activation protein (FAP) in tumor stroma, and tau protein in neurodegenerative disease. These tracers enable more specific visualization of disease processes compared to traditional agents, fitting into a broader shift toward precision imaging in oncology and neurology. In parallel, artificial intelligence (AI) and machine learning techniques are being integrated into tracer development and image analysis. AI-driven methods can accelerate radiopharmaceutical discovery, optimize pharmacokinetic properties, and assist in interpreting complex imaging datasets. This editorial provides an expanded overview of emerging imaging targets and techniques, including theranostic applications that pair diagnosis with radionuclide therapy, and examines how AI is augmenting nuclear medicine. We discuss the implications of these advancements within the field's historical trajectory and address the regulatory, manufacturing, and clinical challenges that must be navigated. Innovations in molecular targeting and AI are poised to transform nuclear medicine practice, enabling more personalized diagnostics and radiotheranostic strategies in the era of precision healthcare.

Artificial intelligence (AI) utilization is growing, but patient perceptions of AI are unclear. Our objective was to understand patient perceptions of AI through a multi-site survey of breast imaging patients. A 36-question survey was distributed to eight US practices (6 academic, 2 non-academic) from October 2023 through October 2024. This manuscript analyzes a subset of questions from the survey addressing digital health literacy and attitudes towards AI in medicine and breast imaging specifically. Multivariable analysis compared responses by respondent demographics. A total of 3,532 surveys were collected (response rate: 69.9%, 3,532/5053). Median respondent age was 55 years (IQR 20). Most respondents were White (73.0%, 2579/3532) and had completed college (77.3%, 2732/3532). Overall, respondents were undecided (range: 43.2%-50.8%) regarding questions about general perceptions of AI in healthcare. Respondents with higher electronic health literacy, more education, and younger age were significantly more likely to consider it useful to use utilize AI for aiding medical tasks (all p<0.001). In contrast, respondents with lower electronic health literacy and less education were significantly more likely to indicate it was a bad idea for AI to perform medical tasks (p<0.001). Non-White patients were more likely to express concerns that AI will not work as well for some groups compared to others (p<0.05). Overall, favorable opinions of AI use for medical tasks were associated with younger age, more education, and higher electronic health literacy. As AI is increasingly implemented into clinical workflows, it is important to educate patients and provide transparency to build patient understanding and trust.

Progression free survival (PFS) is a critical clinical outcome endpoint during cancer management and treatment evaluation. Yet, PFS is often missing from publicly available datasets due to the current subjective, expert, and time-intensive nature of generating PFS metrics. Given emerging research in multi-modal machine learning (ML), we explored the benefits and challenges associated with mining different electronic health record (EHR) data modalities and automating extraction of PFS metrics via ML algorithms. We analyzed EHR data from 92 pathology-proven GBM patients, obtaining 233 corticosteroid prescriptions, 2080 radiology reports, and 743 brain MRI scans. Three methods were developed to derive clinical PFS: 1) frequency analysis of corticosteroid prescriptions, 2) natural language processing (NLP) of reports, and 3) computer vision (CV) volumetric analysis of imaging. Outputs from these methods were compared to manually annotated clinical guideline PFS metrics. Employing data-driven methods, standalone progression rates were 63% (prescription), 78% (NLP), and 54% (CV), compared to the 99% progression rate from manually applied clinical guidelines using integrated data sources. The prescription method identified progression an average of 5.2 months later than the clinical standard, while the CV and NLP algorithms identified progression earlier by 2.6 and 6.9 months, respectively. While lesion growth is a clinical guideline progression indicator, only half of patients exhibited increasing contrast-enhancing tumor volumes during scan-based CV analysis. Our results indicate that data-driven algorithms can extract tumor progression outcomes from existing EHR data. However, ML methods are subject to varying availability bias, supporting contextual information, and pre-processing resource burdens that influence the extracted PFS endpoint distributions. Our scan-based CV results also suggest that the automation of clinical criteria may not align with human intuition. Our findings indicate a need for improved data source integration, validation, and revisiting of clinical criteria in parallel to multi-modal ML algorithm development.

It is unknown whether prediction models for lung function decline using computed tomography (CT) imaging-derived features from the upper lobes improve performance compared with globally derived features in individuals at risk of and with COPD. Individuals at risk (current or former smokers) and those with COPD from the Canadian Cohort Obstructive Lung Disease (CanCOLD) retrospective study, were investigated. A total of 103 CT features were extracted globally and regionally, and were used with 12 clinical features (demographics, questionnaires and spirometry) to predict rapid lung function decline for individuals at risk and those with COPD. Machine-learning models were evaluated in a hold-out test set using the area under the receiver operating characteristic curve (AUC) with DeLong's test for comparison. A total of 780 participants were included (n=276 at risk; n=298 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 COPD; n=206 GOLD 2+ COPD). For predicting rapid lung function decline in those at risk, the upper-lobe CT model obtained a significantly higher AUC (AUC=0.80) than the lower-lobe CT model (AUC=0.63) and global model (AUC=0.66; p<0.05). For predicting rapid lung function decline in COPD, there was no significant differences between the upper-lobe (AUC=0.63), lower-lobe (AUC=0.59) or global CT features model (AUC=059; p>0.05). CT features extracted from the upper lobes obtained significantly improved prediction performance compared with globally extracted features for rapid lung function decline in early/mild COPD.

This study evaluates the impact of artificial intelligence (AI) assistance on the diagnostic performance of radiologists with varying levels of experience in interpreting mammograms in a Malaysian tertiary referral center, particularly in women with dense breasts. A retrospective study including 434 digital mammograms interpreted by two general radiologists (12 and 6 years of experience) and two trainees (2 years of experience). Diagnostic performance was assessed with and without AI assistance (Lunit INSIGHT MMG), using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUC). Inter-reader agreement was measured using kappa statistics. AI assistance significantly improved the diagnostic performance of all reader groups across all metrics (p < 0.05). The senior radiologist consistently achieved the highest sensitivity (86.5% without AI, 88.0% with AI) and specificity (60.5% without AI, 59.2% with AI). The junior radiologist demonstrated the highest PPV (56.9% without AI, 74.6% with AI) and NPV (90.3% without AI, 92.2% with AI). The trainees showed the lowest performance, but AI significantly enhanced their accuracy. AI assistance was particularly beneficial in interpreting mammograms of women with dense breasts. AI assistance significantly enhances the diagnostic accuracy and consistency of radiologists in mammogram interpretation, with notable benefits for less experienced readers. These findings support the integration of AI into clinical practice, particularly in resource-limited settings where access to specialized breast radiologists is constrained.

Currently, there are inconsistencies among different studies on preoperative prediction of Cytokeratin 19 (CK19) expression in HCC using traditional imaging, radiomics, and deep learning. We aimed to systematically analyze and compare the performance of non-invasive methods for predicting CK19-positive HCC, thereby providing insights for the stratified management of HCC patients. A comprehensive literature search was conducted in PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to February 2025. Two investigators independently screened and extracted data based on inclusion and exclusion criteria. Eligible studies were included, and key findings were summarized in tables to provide a clear overview. Ultimately, 22 studies involving 3395 HCC patients were included. 72.7% (16/22) focused on traditional imaging, 36.4% (8/22) on radiomics, 9.1% (2/22) on deep learning, and 54.5% (12/22) on combined models. The magnetic resonance imaging was the most commonly used imaging modality (19/22), and over half of the studies (12/22) were published between 2022 and 2025. Moreover, 27.3% (6/22) were multicenter studies, 36.4% (8/22) included a validation set, and only 13.6% (3/22) were prospective. The area under the curve (AUC) range of using clinical and traditional imaging was 0.560 to 0.917. The AUC ranges of radiomics were 0.648 to 0.951, and the AUC ranges of deep learning were 0.718 to 0.820. Notably, the AUC ranges of combined models of clinical, imaging, radiomics and deep learning were 0.614 to 0.995. Nevertheless, the multicenter external data were limited, with only 13.6% (3/22) incorporating validation. The combined model integrating traditional imaging, radiomics and deep learning achieves excellent potential and performance for predicting CK19 in HCC. Based on current limitations, future research should focus on building an easy-to-use dynamic online tool, combining multicenter-multimodal imaging and advanced deep learning approaches to enhance the accuracy and robustness of model predictions.

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Comorbidities in patients with COPD significantly increase morbidity, mortality, and healthcare costs, posing a significant burden on the management of COPD. Given the complex clinical manifestations and varying severity of COPD comorbidities, accurate diagnosis and evaluation are particularly important in selecting appropriate treatment options. With the development of medical imaging technology, AI-based chest CT, as a noninvasive imaging modality, provides a detailed assessment of COPD comorbidities. Recent studies have shown that certain radiographic features on chest CT can be used as alternative markers of comorbidities in COPD patients. CT-based radiomics features provided incremental predictive value than clinical risk factors only, predicting an AUC of 0.73 for COPD combined with CVD. However, AI has inherent limitations such as lack of interpretability, and further research is needed to improve them. This review evaluates the progress of AI technology combined with chest CT imaging in COPD comorbidities, including lung cancer, cardiovascular disease, osteoporosis, sarcopenia, excess adipose depots, and pulmonary hypertension, with the aim of improving the understanding of imaging and the management of COPD comorbidities for the purpose of improving disease screening, efficacy assessment, and prognostic evaluation.

Knee osteoarthritis (KOA) is a leading cause of disability globally. Early and accurate diagnosis is paramount in preventing its progression and improving patients' quality of life. However, the inconsistency in radiologists' expertise and the onset of visual fatigue during prolonged image analysis often compromise diagnostic accuracy, highlighting the need for automated diagnostic solutions. In this study, we present an advanced deep learning model, OA-HybridCNN (OHC), which integrates ResNet and DenseNet architectures. This integration effectively addresses the gradient vanishing issue in DenseNet and augments prediction accuracy. To evaluate its performance, we conducted a thorough comparison with other deep learning models using five-fold cross-validation and external tests. The OHC model outperformed its counterparts across all performance metrics. In external testing, OHC exhibited an accuracy of 91.77%, precision of 92.34%, and recall of 91.36%. During the five-fold cross-validation, its average AUC and ACC were 86.34% and 87.42%, respectively. Deep learning, particularly exemplified by the OHC model, has greatly improved the efficiency and accuracy of KOA imaging diagnosis. The adoption of such technologies not only alleviates the burden on radiologists but also significantly enhances diagnostic precision.

Lung cancer, one of the most lethal malignancies globally, often presents insidiously as pulmonary nodules. Its nonspecific clinical presentation and heterogeneous imaging characteristics hinder accurate differentiation between benign and malignant lesions, while biopsy's invasiveness and procedural constraints underscore the critical need for non-invasive early diagnostic approaches. In this retrospective study, we analyzed outpatient and inpatient records from the First Medical Center of Chinese PLA General Hospital between 2011 and 2021, focusing on pulmonary nodules measuring 5-30mm on CT scans without overt signs of malignancy. Pathological examination served as the reference standard. Comparative experiments evaluated SVM, RF, XGBoost, FNN, and Atten_FNN using five-fold cross-validation to assess AUC, sensitivity, and specificity. The dataset was split 70%/30%, and stratified five-fold cross-validation was applied to the training set. The optimal model was interpreted with SHAP to identify the most influential predictive features. This study enrolled 3355 patients, including 1156 with benign and 2199 with malignant pulmonary nodules. The Atten_FNN model demonstrated superior performance in five-fold cross-validation, achieving an AUC of 0.82, accuracy of 0.75, sensitivity of 0.77, and F1 score of 0.80. SHAP analysis revealed key predictive factors: demographic variables (age, sex, BMI), CT-derived features (maximum nodule diameter, morphology, density, calcification, ground-glass opacity), and laboratory biomarkers (neuroendocrine markers, carcinoembryonic antigen). This study integrates electronic medical records and pathology data to predict pulmonary nodule malignancy using machine/deep learning models. SHAP-based interpretability analysis uncovered key clinical determinants. Acknowledging limitations in cross-center generalizability, we propose the development of a multimodal diagnostic systems that combines CT imaging and radiomics, to be validated in multi-center prospective cohorts to facilitate clinical translation. This framework establishes a novel paradigm for early precision diagnosis of lung cancer.